Macquarie Group
SCPH

Macquarie Group’s scPharmaceuticals SCPH Stock Holding History

Macquarie Group’s Portfolio SCPH Stock Details SCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-3,486
Closed -$11K – 1926
2019
Q2 		$11K Buy
+3,486
New +$11.4K ﹤0.01% 1799
2019
Q1 		– Sell
-1,400
Closed -$5K – 1976
2018
Q4 		$5K Buy
+1,400
New +$6.58K ﹤0.01% 2108

Other funds holding SCPH

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
AIM
Alambic Investment Management Belvedere, California $9.12M AUM 34.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Macquarie Group's SCPH Position: Q3 2019 in Review

Macquarie Group sold out of scPharmaceuticals (SCPH) in Q3 2019, closing a stake of 3,486 shares — an estimated $11K sold.

Macquarie Group first reported a position in SCPH in Q4 2018 and held it in 2 quarters. The position peaked at $11K in Q2 2019. 26 funds tracked by Wall St. Rank hold SCPH as of Q3 2019.

  • Macquarie Group reported no remaining scPharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Macquarie Group sold 3,486 scPharmaceuticals shares in Q3 2019, an estimated $11K.
  • Macquarie Group first reported a position in scPharmaceuticals in Q4 2018 and held it in 2 quarters.
  • Macquarie Group's scPharmaceuticals position peaked at $11K in Q2 2019.
  • 26 funds tracked by Wall St. Rank held scPharmaceuticals as of Q3 2019.

Based on Macquarie Group's 13F filing for Q3 2019, filed 14 Nov 2019.